Vanda Q3 Loss Narrows to $22.6M; Cash Falls to $140.5M as HETLIOZ Patent Loss and DOJ Threat Land
VNDA is trading near its 52-week low of $3.79 (15% above the low) on elevated volume (2.0× avg).
Summary
Vanda's Q3 loss narrowed to $22.6 million on $69.8 million of revenue, but the 10-Q discloses a September court loss on key HETLIOZ patents and a possible DOJ False Claims Act suit, with cash down to $140.5 million.
Key Events · Earnings and Guidance · VNDA
-
Q3 Loss Narrows on Higher Revenue
Net loss was $22.6 million, or $0.37 per share, versus $62.5 million in Q2, as revenue rose 24% to $69.8 million.
-
Cash Falls to $140.5 Million
Cash, cash equivalents and marketable securities dropped from $263.8 million at December 31, 2025 to $140.5 million at September 30, 2026; management says funding lasts at least 12 months.
-
HETLIOZ Patent Suit Lost
In September 2026 the Delaware District Court granted summary judgment of non-infringement for Teva and Apotex on the '129 and '556 patents, relying in part on the June 2026 Hikma v. Amarin decision; Vanda is evaluating options.
-
DOJ Weighs False Claims Suit
In October 2026 the DOJ notified Vanda it is considering filing a civil complaint under the False Claims Act over historical HETLIOZ practices; no complaint has been filed.
Analysis · VNDA · Life Sciences
The headline numbers were already out on October 28, but the 10-Q carries two items investors did not have: a September 2026 Delaware court ruling granting Teva and Apotex summary judgment of non-infringement on the '129 and '556 HETLIOZ patents, and an October 2026 DOJ notice that it is considering a False Claims Act civil complaint over historical HETLIOZ practices. Both hit the HETLIOZ franchise, which already faces generic competition and fell 21% to $43.2 million for the nine months. Cash and marketable securities dropped to $140.5 million from $263.8 million at year-end, and management still says that is enough for at least 12 months, but the burn makes future financing more likely.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.9M. The 52-week trading range was $3.79 to $9.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.